Published in Hepatitis Weekly, July 3rd, 1995
M.W. Yu, and colleagues, Center for Biologics Evaluation and Research, FDA, said that the detection of HCV RNA in Gammagard lots was in relation to the type of anti-HCV screening that was performed on the starting plasma and the number of case reports received by Baxter Healthcare Corporation, the manufacturer of Gammagard ("Hepatitis C Transmission Associated with Intravenous Immunoglobulins," the Lancet, May 6, 1995;345:1173-1174).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.